favicon-300x300

ERS Genomics

ERS is the world leader in licensing CRISPR/Cas9 technology for a wide variety of applications.
 
Our founder, Dr. Emmanuelle Charpentier (the ‘E’in ERS) won the Nobel Prize for the discovery of CRISPR/Cas9 in 2020. 

Without question, CRISPR/Cas9 has transformed the field of gene editing. 
At ERS Genomics, our purpose is to extend global access to this technology and expand the boundaries of CRISPR potential.
 
 
 

 

BIO International is the perfect time to start or continue a conversation about your CRISPR license. We are excited to connect with companies who can benefit from our game-changing technology. A meeting or a call with us is worthwhile for you if:

You are interested in possible use of CRISPR/Cas9 for internal research programs:
– Are you using modified cells or animals from an academic source?
– Are you generating in-house reagents?

 

You are interested in use of genetically modified cells in manufacturing. Including… 
– mAbs
– Gene or cell therapy
– Vectors
– Industrial enyzmes or intermediates

 

You provide any services that use CRISPR/Cas9 or cells or animals modified by the technology. Including…
– High-throughput screening 
– Target identification, Target validation
– Cell line development
– Disease specific cell models
– Animal models of disease

 

You have an interest in animal health applications. Including… 
Disease resistance, Vaccines Trait improvements

 
 
Drop by our Booth, 2549, to connect or schedule a BIO Partnering meeting.

 

Schedule time with ERS

Jon Kratochvil

 

‘If you’re using or plan to use CRISPR/Cas9
technology, you need a License
from ERS Genomics.’

Connect with us @ Bio Boston in June.
Getting a license is easy, fast & flexible.

Jon Kratochvil, Vice President,  ERS Genonics.

Licensing

Intellectual Property

Knowledge Centre

Contact US

Read More Of Our Articles

Explore more news on CRISPR/Cas9 and how it can provide a leading edge in the highly competitive biotech sector.

ERS Genomics Limited (‘ERS’) completes licensing agreement with Syngene International

Dublin, Ireland – 19/10/2023** – ERS Genomics Limited (‘ERS’) completes licensing agreement with Syngene International, India’s leading Contract Research, Development and Manufacturing Organization. Syngene gains access to ERS Genomics’ foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners.    ERS Genomics,.

Read Full Article

ERS Genomics & Demeetra Enter Into CRISPR/Cas9 Licensing Agreement

ERS Genomics & Demeetra Enter Into CRISPR/Cas9 Licensing Agreement Demeetra to broaden synthetic biology and bioprocessing technology through combined CRISPR/Cas9 IP and Demeetra’s own dimeric Cas-CLOVER. Dublin, Ireland and Kentucky, USA, September 12: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Demeetra AgBio (‘Demeetra’). This.

Read Full Article